PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

The outcome marks the latest setback for the company's Phase 3 SKYSCRAPER-01 study, which evaluated tiragolumab in combination with Roche's (OTCQX:RHHBY) cancer immunotherapy Tecentriq against ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

(RTTNews) - Roche (RHHBY) announced that the U.S. Food and ... Roche NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Genentech, a member of the Roche Group (RHHBY), noted that it continuously ... Roche NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Shares of Poseida Therapeutics Inc. ($PSTX) surged over 200% on Tuesday, reaching levels not seen since August 2021, after ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Roche’s (OTC:RHHBY) member Genentech, announced interim results from a phase III study evaluating Tecentriq and Avastin plus chemotherapy for first-line treatment of... ByZacks Investment ...

Biogen (NASDAQ:BIIB) and its Japan-based partner Eisai announced the discontinuation of two late-stage studies evaluating their Alzheimer’s disease (“AD”)... Roche Holding (SIX:ROG) AG (OTC ...